Non-small Cell Lung Cancer
11
Companies
19
Drug Programs
11
Phase 3
0
Upcoming PDUFAs
Novartis AG
Pemetrexed
Regeneron Pharmaceuticals, Inc.
Libtayo
Eli Lilly and Company
Erlotinib
Eli Lilly and Company
Gemcitabine
Eli Lilly and Company
cisplatin
Eli Lilly and Company
pemetrexed
Eli Lilly and Company
docetaxel
BioNTech SE
Pembrolizumab
Eli Lilly and Company
dexamethasone
Ionis Pharmaceuticals, Inc.
Paclitaxel
Cellectar Biosciences, Inc.
Paclitaxel
Sanofi
oxaliplatine / gemcitabine / Vinorelbine
BioNTech SE
Docetaxel
Gritstone bio, Inc.
GRT-C901
Geron Corporation
Bevacizumab
BioNTech SE
BNT327
Gritstone bio, Inc.
GRT-C903
Black Diamond Therapeutics, Inc.
silevertinib (BDTX-1535) monotherapy
Revolution Medicines, Inc.
RMC-4630
| Company | Drug | Phase | Designations | Timeline | Trial ID |
|---|---|---|---|---|---|
| NVS Novartis AG | Pemetrexed | Phase 3 | — | — | — |
| REGN Regeneron Pharmaceuticals, Inc. | Libtayo | Phase 3 | FT | — | — |
| LLY Eli Lilly and Company | Erlotinib | Phase 3 | — | — | — |
| LLY Eli Lilly and Company | Gemcitabine | Phase 3 | — | — | — |
| LLY Eli Lilly and Company | cisplatin | Phase 3 | — | — | — |
| LLY Eli Lilly and Company | pemetrexed | Phase 3 | — | — | — |
| LLY Eli Lilly and Company | docetaxel | Phase 3 | — | — | — |
| BNTX BioNTech SE | Pembrolizumab | Phase 3 | — | — | — |
| LLY Eli Lilly and Company | dexamethasone | Phase 3 | — | — | — |
| IONS Ionis Pharmaceuticals, Inc. | Paclitaxel | Phase 3 | — | — | — |
| CLRB Cellectar Biosciences, Inc. | Paclitaxel | Phase 3 | — | — | — |
| SNY Sanofi | oxaliplatine / gemcitabine / Vinorelbine | Phase 2 | — | — | — |
| BNTX BioNTech SE | Docetaxel | Phase 2 | — | — | — |
| GRTS Gritstone bio, Inc. | GRT-C901 | Phase 2 | — | — | — |
| GERN Geron Corporation | Bevacizumab | Phase 2 | — | — | — |
| BNTX BioNTech SE | BNT327 | Phase 2 | — | — | — |
| GRTS Gritstone bio, Inc. | GRT-C903 | Phase 2 | — | — | — |
| BDTX Black Diamond Therapeutics, Inc. | silevertinib (BDTX-1535) monotherapy | Phase 2 | — | — | — |
| RVMD Revolution Medicines, Inc. | RMC-4630 | Phase 2 | — | — | — |
Not Financial Advice
All predictions are probabilistic and based on historical data. Past performance does not guarantee future results. Consult a qualified financial advisor.